Exploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Federal de Uberlândia (UFU)-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorUniversidade Estadual de Campinas (UNICAMP)-
Autor(es): dc.contributorDonostia International Physics Center– DIPC-
Autor(es): dc.creatorMartins, Daniel Oliveira Silva-
Autor(es): dc.creatorRuiz, Uriel Enrique Aquino-
Autor(es): dc.creatorSantos, Igor Andrade-
Autor(es): dc.creatorOliveira, Igor Santos-
Autor(es): dc.creatorGuevara-Vega, Marco-
Autor(es): dc.creatorde Paiva, Raphael Enoque Ferraz-
Autor(es): dc.creatorAbbehausen, Camilla-
Autor(es): dc.creatorSabino-Silva, Robinson-
Autor(es): dc.creatorCorbi, Pedro Paulo-
Autor(es): dc.creatorJardim, Ana Carolina Gomes-
Data de aceite: dc.date.accessioned2025-08-21T20:55:54Z-
Data de disponibilização: dc.date.available2025-08-21T20:55:54Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2024-10-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1007/s43440-024-00635-z-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/300892-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/300892-
Descrição: dc.descriptionBackground: Currently, there is no antiviral licensed to treat chikungunya fever, a disease caused by the infection with Alphavirus chikungunya (CHIKV). Treatment is based on analgesic and anti-inflammatory drugs to relieve symptoms. Our study aimed to evaluate the antiviral activity of sulfadoxine (SFX), an FDA-approved drug, and its derivatives complexed with silver(I) (AgSFX), salicylaldehyde Schiff base (SFX-SL), and with both Ag and SL (AgSFX-SL) against CHIKV. Methods: The anti-CHIKV activity of SFX and its derivatives was investigated using BHK-21 cells infected with CHIKV-nanoluc, a marker virus-carrying nanoluciferase reporter. Dose-response and time of drug-addition assays were performed in order to assess the antiviral effects of the compounds, as well as in silico data and ATR-FTIR analysis for insights on their mechanisms of action. Results: The SFX inhibited 34% of CHIKV replication, while AgSFX, SFX-SL, and AgSFX-SL enhanced anti-CHIKV activity to 84%, 89%, and 95%, respectively. AgSFX, SFX-SL, and AgSFX-SL significantly decreased viral entry and post-entry to host cells, and the latter also protected cells against infection. Additionally, molecular docking calculations and ATR-FTIR analysis demonstrated interactions of SFX-SL, AgSFX, and AgSFX-SL with CHIKV. Conclusions: Collectively, our findings suggest that the addition of metal ions and/or Schiff base to SFX improved its antiviral activity against CHIKV.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-
Descrição: dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)-
Descrição: dc.descriptionInstitute of Biomedical Science - ICBIM Federal University of Uberlândia - UFU, Avenida Amazonas, 4C- Room 216, Umuarama, MG-
Descrição: dc.descriptionInstitute of Bioscience Language and Exact Sciences - IBILCE São Paulo State University - UNESP, SP-
Descrição: dc.descriptionInstitute of Chemistry University of Campinas - UNICAMP, SP-
Descrição: dc.descriptionDonostia International Physics Center– DIPC, Paseo Manuel de Lardizabal 4, 20018 Donostia, Euskadi,Gipuzkoa-
Descrição: dc.descriptionInstitute of Bioscience Language and Exact Sciences - IBILCE São Paulo State University - UNESP, SP-
Descrição: dc.descriptionFAPESP: 2021/08717-8-
Descrição: dc.descriptionFAPESP: 2021/10265-8-
Descrição: dc.descriptionCNPq: 307207/2021-8; 465669/2014-0-
Descrição: dc.descriptionCNPq: 308474/2021-6-
Descrição: dc.descriptionCNPq: 403193/2022-2; #142495/2020-4-
Descrição: dc.descriptionCNPq: 409187/2023-2-
Descrição: dc.descriptionCAPES: 88887.506792/2020-00)-
Descrição: dc.descriptionFAPEMIG: APQ-01487-22-
Descrição: dc.descriptionFAPEMIG: APQ-02148-21-
Descrição: dc.descriptionFAPEMIG: APQ-04686-22-
Descrição: dc.descriptionCAPES: CAPES.PrInt-UFU sandwich scholarship #88887.700246/2022-00-
Descrição: dc.descriptionCAPES: Finance Code 001; #142495/2020-4-
Formato: dc.format1147-1159-
Idioma: dc.languageen-
Relação: dc.relationPharmacological Reports-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAntiviral-
Palavras-chave: dc.subjectArboviruses-
Palavras-chave: dc.subjectChikungunya virus-
Palavras-chave: dc.subjectSchiff base-
Palavras-chave: dc.subjectSilver(I)-
Palavras-chave: dc.subjectSulfadoxine-
Título: dc.titleExploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.